Sunshine Biopharma, Inc. (SBFM)
NASDAQ: SBFM · Real-Time Price · USD
0.980
-0.002 (-0.22%)
At close: Apr 28, 2026, 4:00 PM EDT
0.980
+0.000 (0.01%)
After-hours: Apr 28, 2026, 4:22 PM EDT
Sunshine Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 36.31 | 34.87 | 24.09 | 4.35 | 0.23 | Upgrade
|
| Revenue Growth (YoY) | 4.11% | 44.75% | 454.42% | 1802.41% | 219.88% | Upgrade
|
| Cost of Revenue | 24.05 | 24.2 | 15.75 | 2.65 | 0.12 | Upgrade
|
| Gross Profit | 12.26 | 10.67 | 8.34 | 1.7 | 0.11 | Upgrade
|
| Selling, General & Admin | 15.33 | 14.94 | 10.83 | 9.48 | 1.87 | Upgrade
|
| Research & Development | 0.6 | 0.93 | 1.86 | 0.81 | 0.67 | Upgrade
|
| Other Operating Expenses | 0.47 | 0.39 | 0.29 | 0.06 | - | Upgrade
|
| Operating Expenses | 16.73 | 16.48 | 13.12 | 10.37 | 2.55 | Upgrade
|
| Operating Income | -4.48 | -5.81 | -4.79 | -8.67 | -2.44 | Upgrade
|
| Interest Expense | - | -0.01 | -0.14 | -0.04 | -0.33 | Upgrade
|
| Interest & Investment Income | 0.28 | 0.5 | 0.81 | 0.52 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 0 | -0.04 | -0 | -0 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -4.2 | -5.37 | -4.11 | -8.2 | -2.77 | Upgrade
|
| Impairment of Goodwill | - | - | - | -18.33 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.01 | - | - | - | - | Upgrade
|
| Asset Writedown | -1.75 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 0.01 | -9.67 | Upgrade
|
| Pretax Income | -5.95 | -5.37 | -4.11 | -26.51 | -12.44 | Upgrade
|
| Income Tax Expense | 0.02 | -0.23 | 0.4 | 0.23 | - | Upgrade
|
| Earnings From Continuing Operations | -5.98 | -5.13 | -4.51 | -26.74 | -12.44 | Upgrade
|
| Net Income | -5.98 | -5.13 | -4.51 | -26.74 | -12.44 | Upgrade
|
| Net Income to Common | -5.98 | -5.13 | -4.51 | -26.74 | -12.44 | Upgrade
|
| Shares Outstanding (Basic) | 4 | 1 | 0 | - | - | Upgrade
|
| Shares Outstanding (Diluted) | 4 | 1 | 0 | - | - | Upgrade
|
| Shares Change (YoY) | 492.39% | 5371.73% | - | - | - | Upgrade
|
| EPS (Basic) | -1.44 | -7.32 | -351.35 | - | - | Upgrade
|
| EPS (Diluted) | -1.44 | -7.32 | -351.35 | - | - | Upgrade
|
| Free Cash Flow | -5.51 | -14.18 | -8.86 | -5.44 | -1.83 | Upgrade
|
| Free Cash Flow Per Share | -1.32 | -20.21 | -690.63 | - | - | Upgrade
|
| Gross Margin | 33.76% | 30.59% | 34.61% | 39.04% | 48.42% | Upgrade
|
| Operating Margin | -12.34% | -16.67% | -19.86% | -199.61% | -1068.24% | Upgrade
|
| Profit Margin | -16.46% | -14.72% | -18.70% | -615.44% | -5444.41% | Upgrade
|
| Free Cash Flow Margin | -15.16% | -40.67% | -36.76% | -125.24% | -800.75% | Upgrade
|
| EBITDA | -4.15 | -5.59 | -4.64 | -8.65 | -2.43 | Upgrade
|
| EBITDA Margin | -11.42% | -16.02% | -19.24% | -199.03% | - | Upgrade
|
| D&A For EBITDA | 0.33 | 0.22 | 0.15 | 0.03 | 0.01 | Upgrade
|
| EBIT | -4.48 | -5.81 | -4.79 | -8.67 | -2.44 | Upgrade
|
| EBIT Margin | -12.34% | -16.67% | -19.86% | -199.61% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.